VIA-3196: Phase I started

Madrigal began a double-blind, placebo-controlled U.S. Phase I trial to evaluate multiple ascending-doses of oral 3196 daily for 14 days in about 40 healthy volunteers with mildly elevated LDL-C. Madr...